Leukemia And B Cell Lymphoma Articles & Analysis
22 news found
Almost anyone with a weakened or suppressed immune system could be at a heightened risk of developing an invasive mold infection (IMI). Two of the most common IMIs include invasive aspergillosis and invasive mucormycosis. The Centers for Disease Control and Prevention (CDC) warns that IMIs can occur days to weeks after exposure to fungi that live in the environment. The agency goes so far as to ...
Anyone with a weakened or suppressed immune system could be at heightened risk of developing an invasive mold infection. The Centers for Disease Control and Prevention (CDC) warns that these types of infections can occur days to weeks after exposure to fungi that live in the environment. The agency goes so far as to advise physicians to keep invasive mold infections in mind when treating people ...
The company aims to translate unique scientific insights in myeloid cell biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that inhibit immune suppression in the tumor microenvironment. ...
The company aims to translate unique scientific insights in myeloid cell biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that inhibit immune suppression in the tumor microenvironment. ...
In the context of solid tumors, preclinical data presented at the 2021 American Association for Cancer Research annual meeting demonstrate that IO-202 enhances dendritic cell function and T cell activation in vitro and inhibits tumor growth in an immune competent model in vivo. IO-202 has two ongoing clinical studies in the U.S.: Its first Phase 1 trial is ...
The company aims to translate unique scientific insights in myeloid cell biology and immune inhibitory receptors to discover and develop first-in-class biotherapeutics that inhibit immune suppression in the tumor microenvironment. ...
NEW YORK, July 12, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced an appointment to its executive team to lead the Company’s business development efforts. Kenneth R. LaMontagne, Ph.D., joins the company as Senior ...
ABOUT LILRB2 (ILT4) LILRB2, also known as ILT4, is expressed mostly by myeloid cells, including monocytes, macrophages, dendritic cells, and neutrophils. ...
” ABOUT LAIR1 LAIR1 is an immune inhibitory receptor of the Leukocyte Immunoglobulin-Like Receptor subfamily B (LILRB) and is expressed on lymphocytes and myeloid cells. Research shows that LAIR1 expression correlates with worse survival in several cancers. ...
This research has rapidly advanced a completely new field of study and class of cancer immunotherapy that goes beyond T cells to overcome immune resistance and the limitations of current treatment options. ...
AVM Biotechnology, a clinical stage company developing AVM0703, a small molecule that mobilizes endogenous gamma delta TCR+ and invariant TCR+ bispecific Natural Killer T-like cells, announced the expansion of its senior management with the appointment of Brian Andersen as Chief Commercial Officer and Pearl Chan as Chief Financial Officer. These seasoned industry leaders will help drive the ...
GAITHERSBURG, Md., Jan. 18, 2022 (GLOBE NEWSWIRE) -- NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Scott Carmer, Chief Executive Officer, will participate in the LLS TAP panel discussion entitled ...
AVM Biotechnology, a clinical-stage company, announced today FDA permission to modify its ongoing clinical study, AVM0703-001, entitled “The WWRD Study: AVM0703 for Treatment of Leukemia or Lymphoma”. The initial protocol, a 3 x 3-based design, called for dose escalation of 3 mg/kg for each of the six cohorts, ranging from 6 mg/kg to 21 mg/kg, with a minimum of three patients per ...
Thermo Fisher Scientific Inc. has made a donation to the Leukemia & Lymphoma Society in recognition of the recent U.S. Food and Drug Administration approval of the first CAR T cell immunotherapy for multiple myeloma developed by Bristol Myers Squibb and bluebird bio. Abecma® (idecabtagene vicleucel; ide-cel) is a chimeric antigen ...
MicroVaccines SA (from now on “MV”) has been officially incorporated in Canton Ticino on October 26th, 2018 as a spin-off of the Institute for Research in Biomedicine (from now on “IRB”) by Dr. Fabio Grassi, M.D., Ph.D. “This is an incredible achievement for a researcher and M.D., whose ambition is to translate experimental findings to medical application” ...
SFA Therapeutics’ CEO Dr Ira Spector presents an overview of the company and its platform technology SFA Overview Presentation on YouTube Introduction to SFA Liver Disease and Oncology Programs. SFA Oncology More information here We received US Patent 10,143,669B2; to prevent Hepatitis B progression to HCC, a liver cancer that affects 400 million patients and causes 1 million cancer ...
Today, the IAQ Video Network and Cochrane & Associates announced the release of their latest educational video. Their newest production discusses the industrial chemical known as vinyl chloride and potential exposure concerns. “Vinyl chloride is an important industrial chemical that is produced in large quantities as a chemical intermediate for manufacturing other products, such ...
Anti-TdT, also a rabbit monoclonal antibody, is used to help classify lymphoma and leukemia by staining terminal deoxynucleotidyl transferase (TdT) in tissue samples. In immunohistochemistry, antibodies to TdT can be used to demonstrate the presence of pre-T and pre-B cells and multipotent hematopoietic stem ...
The U.S. Environmental Protection Agency (EPA) announced today its plan to address the four draft Integrated Risk Information System (IRIS) assessments that were placed on hold in June 2010, pending a review of some of the underlying studies relied on in the assessments. EPA conducts IRIS assessments to determine the potential impact of specific chemicals on people’s health. The four ...
To address ongoing health disparities and hardships encountered by millions of American families, the men and women of Blue Cross and Blue Shield of Georgia, (BCBSGA) and its corporate foundation, proudly continued the company's tradition of caring for the people it serves and the health of our communities by contributing $1,279,779 to philanthropic and civic organizations throughout Georgia in ...